Alnylam Pharmaceuticals (NASDAQ:ALNY) Cut to “Hold” at StockNews.com

StockNews.com lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a buy rating to a hold rating in a research report released on Thursday morning.

A number of other research analysts also recently issued reports on ALNY. Chardan Capital reiterated a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Citigroup boosted their price objective on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Bank of America boosted their price objective on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Wolfe Research downgraded shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. Finally, Barclays boosted their price objective on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Trading Up 0.2 %

NASDAQ ALNY opened at $253.74 on Thursday. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $304.39. The firm has a 50 day simple moving average of $271.93 and a 200-day simple moving average of $240.19. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The firm has a market cap of $32.73 billion, a price-to-earnings ratio of -96.85 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same period in the prior year, the company earned $1.15 EPS. The firm’s revenue was down 33.3% compared to the same quarter last year. Equities research analysts anticipate that Alnylam Pharmaceuticals will post -2.21 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 5,219 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the transaction, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at $19,797,302.40. This represents a 6.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Pushkal Garg sold 1,682 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the sale, the chief marketing officer now directly owns 17,457 shares in the company, valued at approximately $4,381,357.86. The trade was a 8.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 8,370 shares of company stock valued at $2,100,703 in the last ninety days. 1.50% of the stock is currently owned by company insiders.

Institutional Trading of Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Tidal Investments LLC increased its stake in shares of Alnylam Pharmaceuticals by 75.1% during the 3rd quarter. Tidal Investments LLC now owns 20,544 shares of the biopharmaceutical company’s stock worth $5,650,000 after purchasing an additional 8,811 shares in the last quarter. Sanctuary Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Sanctuary Advisors LLC now owns 4,558 shares of the biopharmaceutical company’s stock valued at $1,254,000 after buying an additional 2,181 shares during the last quarter. Teachers Retirement System of The State of Kentucky increased its position in Alnylam Pharmaceuticals by 4.5% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 34,713 shares of the biopharmaceutical company’s stock worth $9,547,000 after buying an additional 1,500 shares in the last quarter. Toronto Dominion Bank raised its holdings in shares of Alnylam Pharmaceuticals by 27.3% in the third quarter. Toronto Dominion Bank now owns 15,466 shares of the biopharmaceutical company’s stock worth $4,254,000 after acquiring an additional 3,315 shares during the last quarter. Finally, Coldstream Capital Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 43.7% in the third quarter. Coldstream Capital Management Inc. now owns 1,211 shares of the biopharmaceutical company’s stock valued at $329,000 after acquiring an additional 368 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.